Rhythm Biosciences Ltd. announced the appointment of one of the more experienced and respected leaders in Australia's MedTech industry, Ms Sue MacLeman as an independent, Non-Executive Director, effective immediately. Sue has more than 30 years' experience as a pharmaceutical, biotechnology and medical technology ex-ecutive having held senior roles in corporate, medical, commercial and business development at Schering- Plough Corporation (now Merck), Amgen, Bristol-Myers Squibb and Mesoblast. Sue has also served as CEO and a Board member of several ASX, AIM and NASDAQ listed companies in the Healthtech sector.

Sue is currently the Chair of the Medical Technologies and Pharmaceuticals Growth Centre (MTPConnect). Sue is a Non Executive Director of Planet Innovation Holdings Ltd, ATSE and OMICO (Australian Genomic Cancer Medicines Ltd). Sue is also a member of the NSW Innovation and Productivity Council, Fellow of the Australian Academy of Technology and Engineering (ATSE) and Fellow/Graduate of Australian Institute of Company Directors (AICD).

Sue is also appointed to several academic and government advisory boards. Sue brings a unique set of experiences in technology commercialisation, strategic planning, capital markets and fund raising, M&A and alliance management. Her broad commercial and technical experience is underpinned by a Bachelor of Pharmacy from the University of Queensland, a Master of Laws from Deakin University and a Master of Marketing from Melbourne Business School.